Pacira Pharmaceuticals, Inc.

10450 Science Center Drive
San Diego, CA 92121
(858) 625 2424

5 Sylvan Way
Parsippany, NJ 07054
(973) 254 3560

TAKING CARE OF PATIENTS, TODAY AND TOMORROW

Online Investor Kit

Assemble your own Investor Kit by selecting and printing from the following documents.

Corporate Presentation

DateTitle
11/24/14
Corporate Presentation

Recent SEC Filings

<< First | Previous | Next | Last >>
Filing DateFormDescriptionFiling GroupDownloads
12/08/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
11/25/14CT ORDERCT ORDEROther Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
11/12/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
11/12/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
11/04/144Statement of changes in beneficial ownership of securities3,4,5 Download SEC Filing to Word Excel SEC Filing Unavailable Download SEC Filing to Adobe PDF XBRL SEC Filing Unavailable
<< First | Previous | Next | Last >>

Fact Sheets

There are currently no items available.

Recent Press Releases

DateTitle 
12/12/14Pacira Pharmaceuticals Inc. Announces Changes to EXPAREL® Label
PARSIPPANY, N.J.--(BUSINESS WIRE)--Dec. 12, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the U.S. Food and Drug Administration’s (FDA) approval of changes to the EXPAREL packaging and label proposed by the Company as part of a routine label supplement application, submitted on November 27, 2013. The approved label changes are limited to revisions pertaining to the product’s storage, instructions of use and use in special popu... 
Printer Friendly Version
11/25/14Pacira Pharmaceuticals, Inc. to Present at the 26th Annual Piper Jaffray Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 25, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the 26th Annual Piper Jaffray Healthcare Conference on Tuesday, December 2, 2014, at 8:30 a.m. ET in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the Pacira... 
Printer Friendly Version
11/11/14Pacira Pharmaceuticals, Inc. to Present at the Jefferies 2014 Global London Healthcare Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 11, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Jefferies 2014 Global London Healthcare Conference at 10:40 a.m. GMT (5:40 a.m. ET) on Wednesday, Nov. 19, 2014, in London. Mr. Stack is expected to present an overview of the company. A live audio webc... 
Printer Friendly Version
11/06/14Pacira Pharmaceuticals Inc. Announces New Data on the Use of EXPAREL to Treat Postsurgical Pain Following Total Knee Arthroplasty
-- Data Presented at the 2014 Annual Meeting of the American Association of Hip and Knee Surgeons Finds Lower Patient-Perceived Pain Scores, Reduced Opioid Consumption and Improved Patient Satisfaction in Patients Who Received EXPAREL – PARSIPPANY, N.J.--(BUSINESS WIRE)--Nov. 6, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results of an independent, physician-initiated study designed to evaluate the difference in p... 
Printer Friendly Version
10/30/14Pacira Pharmaceuticals, Inc. Reports Third Quarter EXPAREL Revenue of $50.2 Million and Third Quarter 2014 Results
Company Will Host Conference Call Today at 9 a.m. ET PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 30, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today provided updates on the success of EXPAREL® (bupivacaine liposome injectable suspension) for postsurgical pain in the United States and announced consolidated financial results for the third quarter ended September 30, 2014. “The third quarter marked another period of consisten... 
Printer Friendly Version
10/27/14New Study Correlates Use of EXPAREL for Postsurgical Pain Management with Significant Reductions in Opioid Related Adverse Events
--Data from American College of Surgeons Demonstrates Reduced Incidence of Respiratory Depression, Urinary Retention and Fall Risk in Patients Receiving EXPAREL-- PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 27, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced results of an independent, physician-initiated study that reinforce the positive impact of an EXPAREL-based pain management regimen on reducing postsurgical complicat... 
Printer Friendly Version
10/15/14Pacira Pharmaceuticals Announces Timing for Third Quarter 2014 Financial Results Webcast and Conference Call
PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 15, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ:PCRX) today announced that financial results for the company’s third quarter ended September 30, 2014, will be released before the market opens on Thursday, October 30, 2014. The Pacira management team will host a conference call to discuss the company’s financial results and recent and upcoming developments on Thursday, October 30, 2014, at 9 a.m. ET. The call... 
Printer Friendly Version
10/13/14Pacira Pharmaceuticals, Inc. Announces Additional Data Supporting Safety of EXPAREL® in Peripheral Nerve Block
-- Analysis Presented at the 2014 Annual Meeting of the American Society of Anesthesiologists Finds the Safety of EXPAREL Similar to Placebo and Bupivacaine HCl -- PARSIPPANY, N.J.--(BUSINESS WIRE)--Oct. 13, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced data demonstrating that EXPAREL® (bupivacaine liposome injectable suspension) used in peripheral nerve blocks has comparable safety to placebo and bupivacaine HCl. T... 
Printer Friendly Version
09/25/14Pacira Pharmaceuticals, Inc. Announces Receipt of FDA Warning Letter
PARSIPPANY, N.J.--(BUSINESS WIRE)--Sep. 25, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced the receipt of a Warning Letter (attached for reference) from the U.S. Food and Drug Administration’s (FDA) Office of Prescription Drug Promotion (OPDP) referencing certain promotional materials on EXPAREL® (bupivacaine liposome injectable suspension). “We take regulatory compliance very seriously and believe that our ... 
Printer Friendly Version
08/05/14Pacira Pharmaceuticals, Inc. to Present at the Wedbush 2014 Life Sciences Management Access Conference
PARSIPPANY, N.J.--(BUSINESS WIRE)--Aug. 5, 2014-- Pacira Pharmaceuticals, Inc. (NASDAQ: PCRX) today announced that Dave Stack, president, chief executive officer and chairman of Pacira Pharmaceuticals, is scheduled to present at the Wedbush 2014 Life Sciences Management Access Conference on Tuesday, August 12, 2014, at 8:35 a.m. ET in New York. Mr. Stack is expected to present an overview of the company. A live audio webcast of the ... 
Printer Friendly Version
>> Access Older Press Releases
Contact Investor Relations:
Jessica Cho
(973) 254-3574
Jessica.Cho@pacira.com